Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
Company Research
Source: Business Wire
Officinae Bio’s breakthroughs in AI-enabled methodologies for nucleic manufacturing to enhance Maravai’s mRNA manufacturing capabilities within the TriLink BioTechnologies business SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies.Based in Venice, Italy, Officinae Bio is a privately held technology company with a proprietary digital platform to support the biological design of therapeutics. The novel technology enables rapid prototyping of mRNA candidates to test diverse combinations of CAP analogs, chemistry modifications, and sequence designs for client discovery programs. Officinae Bio’s portfolio of technology and s
Show less
Read more
Impact Snapshot
Event Time:
MRVI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRVI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRVI alerts
High impacting Maravai LifeSciences Holdings, Inc. - Class A common stock news events
Weekly update
A roundup of the hottest topics
MRVI
News
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.MarketBeat
- Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsGlobeNewswire
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.MarketBeat
- Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]Yahoo! Finance
- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
MRVI
Earnings
- 11/7/24 - Beat
MRVI
Sec Filings
- 12/18/24 - Form 8-K
- 12/17/24 - Form 4
- 12/9/24 - Form 4
- MRVI's page on the SEC website